2-Mercaptoethane sulfonic acid sodium salt, 96%
2-Mercaptoethane sulfonic acid sodium salt, 96%
2-Mercaptoethane sulfonic acid sodium salt, 96%
Thermo Scientific Chemicals

2-Mercaptoethane sulfonic acid sodium salt, 96%

CAS: 19767-45-4 | C2H5NaO3S2 | 164.169 g/mol
Have Questions?
Change viewbuttonViewtableView
Quantity:
10 g
25 g
Catalog number J63989.09
also known as J63989-09
Price (EUR)
125,00
Each
Quantity:
10 g
Request bulk or custom format
Price (EUR)
125,00
Each
Specifications
Beilstein3657828
CAS19767-45-4
Chemical Name or Material2-Mercaptoethane sulfonic acid sodium salt
ColorWhite
EINECS Number243-285-9
View more
2-Mercaptoethane sulfonic acid sodium salt is used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is used as an antioxidant and cytoprotective agent in a wide variety of applications from protection from toxicity of therapeutic agents, such as cyclophosphamide to prevention from brain injury damage.

This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

Applications
2-Mercaptoethane sulfonic acid sodium salt is used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is used as an antioxidant and cytoprotective agent in a wide variety of applications from protection from toxicity of therapeutic agents, such as cyclophosphamide to prevention from brain injury damage.

Solubility
Soluble in water. Also soluble in methanol, DMSO (33 mg/ml) and ethanol (<1mg/mL).

Notes
Stable under recommended storage conditions. Incompatible with oxidizing agents.
RUO – Research Use Only

General References:

  1. Ariela Marshall; Cindy McGrath; Drew Torigian; Nicholas Papanicolaou; Priti Lal; Carol Kaplan Tweed. Low-dose cyclophosphamide associated with hemorrhagic cystitis in a breast cancer patient. Breast Journal. 2012, 18,(3), 272-275.
  2. Nicole J.Look Hong; Francis J.Hornicek; David C.Harmon; Edwin Choy; Yen-Lin Chen; Sam S.Yoon; G.Petur Nielsen; Jackie Szymonifka; Beow Y.Yeap; Thomas F.DeLaney; John T.Mullen. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year single institution retrospective study. European Journal of Cancer. 2013, 49,(4), 875-883.